Contract Pharma Solutions, UAB - financials and debts

Company age: 13 y. 6 mo.

Update

Contract Pharma Solutions - Company finances

EUR
2018
From: 2018-01-01
To: 2018-12-31
2019
From: 2019-01-01
To: 2019-12-31
2020
From: 2020-01-01
To: 2020-12-31
2021
From: 2021-01-01
To: 2021-12-31
2022
From: 2022-01-01
To: 2022-12-31
2023
From: 2023-01-01
To: 2023-12-31
2024
From: 2024-01-01
To: 2024-12-31
2025
From: 2025-01-01
To: 2025-12-31
Financial data
Sales revenue 565,235 1,098,897 2,172,650 2,790,429 2,174,272 3,707,376 5,921,201 7,583,527
Profit before tax 97,878 122,682 707,223 441,057 2,346 748,363 1,833,191 844,813
Net profit 85,273 108,646 601,088 374,176 1,445 639,955 1,554,460 708,709
Equity 64,794 173,440 774,561 1,148,727 1,150,170 1,790,125 3,344,934 3,954,742
Liabilities 168,932 258,127 272,465 570,896 355,870 697,597 - 1,333,313
Non-current assets 93,501 223,076 400,554 799,353 768,228 678,926 1,361,336 1,626,711
Current assets 140,225 208,491 646,472 920,270 737,812 1,808,596 - 3,658,210
Total assets 233,726 431,567 1,047,026 1,719,623 1,506,040 2,487,522 1,361,336 5,284,921
Taxes paid
STI taxes - - - - - 66,505 288,024 831,863
Social insurance contributions - - - - - 201,292 311,834 430,339
Financial indicators
Revenue change y/y +131.3% +94.4% +97.7% +28.4% -22.1% +70.5% +59.7% +28.1%
ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. 36.5% 25.2% 57.4% 21.8% 0.1% 25.7% 114.2% 13.4%
ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. 131.6% 62.6% 77.6% 32.6% 0.1% 35.7% 46.5% 17.9%
Profit margin Net profit margin. Shows the overall profitability of the company. 15.1% 9.9% 27.7% 13.4% 0.1% 17.3% 26.3% 9.3%
EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. 17.3% 11.2% 32.6% 15.8% 0.1% 20.2% 31.0% 11.1%
Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. 2.6 1.5 0.4 0.5 0.3 0.4 - 0.3
Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. 39,435 65,934 83,297 84,558 59,433 95,469 117,835 127,633

Purchase full financial statements

Profit/Loss, Balance Sheet, Cash Flow, Equity

9.99 € + PVM Buy

Sales revenue

See Scoris data in Google Search

Mark Scoris as a favorite source. One click, no registration.

Contract Pharma Solutions - Social security debts

From To Debt, €
2026-01-21 2026-02-08 8.42
2025-11-18 2025-11-20 19.61
2025-05-16 2025-05-18 45832.91

Contract Pharma Solutions - VMI tax arrears

From To Overdue, €
2025-12-30 2025-12-30 4526.6
2025-12-23 2025-12-29 4518.41
2025-12-18 2025-12-22 4511.39
2025-06-19 2025-06-23 8.35
2024-10-02 2024-10-16 1.67

VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.

Analysis of the company's financial position

This description was generated by artificial intelligence. Report if inaccurate.
Contract Pharma Solutions, UAB (code 303013034) is a Private Limited Liability Company engaged in Manufacture of other food products n.e.c. In 2025, the company generated revenue of €7.58M, up 28.1% year on year and 104.5% over two years. Net profit for the latest year was €708.7K, with a profit margin of 9.3%, following a stronger 2024 result of €1.55M on €5.92M revenue and €640.0K in 2023 on €3.71M revenue. The three-year trend shows rapid sales expansion, while profitability peaked in 2024 and then moderated in 2025. Total assets increased to €5.28M in 2025 from €4.25M in 2024 and €2.49M in 2023. Equity stood at €3.95M, compared with liabilities of €1.33M, indicating a strong balance sheet position. Key efficiency indicators for 2025 were return on equity of 17.9%, return on assets of 13.4%, debt-to-equity of 0.34, and asset turnover of 1.43x. Revenue per employee was €128.5K, while profit per employee was €12.0K.